Kidney Cancer Weekly

May 04, 2026

Videos

Peer-to-Peer Clinical Conversations

Phase II NESCIO Trial of Neoadjuvant Immunotherapy in Renal Cell Carcinoma - Femke Burgers

Pedro Barata speaks with Femke Burgers about the NESCIO trial, an investigator-initiated phase II study evaluating neoadjuvant immunotherapy in patients with intermediate to high-risk clear cell renal cell carcinoma.

View

KIM-1 Biomarker Data from Adjuvant Immunotherapy Trials in Renal Cell Carcinoma - Wenxin Xu

Wenxin Xu

Pedro Barata hosts Wenxin Xu to discuss KIM-1 (Kidney Injury Molecule 1) as an emerging biomarker in renal cell carcinoma.

View

Beyond the Abstracts

Immunotherapy Combinations in Favourable Risk Score Metastatic Renal Cell Carcinoma, an Individual Patients Data Metanalysis - Beyond the Abstract

Clinical, Pathologic, and Genetic Correlates of Nuclear Grade in von Hippel-Lindau-associated Renal Cell Carcinoma - Beyond the Abstract

Conference Coverage

EAU 2026: Adjuvant Pembrolizumab + Belzutifan for Clear Cell RCC: Primary and Exploratory Efficacy Outcomes from the Phase 3 LITESPARK-022 Study

SES AUA 2026: Impact of Cytoreductive Nephrectomy for RCC with Tumor Thrombus: Results from the Intercontinental Collaboration of RCC

EAU 2026: Impact of 89Zr-girentuximab PET Versus Conventional Imaging on Clinical Decision-making in Patients with Indeterminate Renal Masses (ZIRCON-X)

ASCO GU 2026: KEYMAKER-U03 Substudy 03B: Novel Investigative Regimens for Previously Treated Advanced Clear Cell RCC

ASCO GU 2026: Fruquintinib + Serplulimab as First Line Therapy in Metastatic or Unresectable Non-Clear Cell RCC: Updated Efficacy and Safety Data from a Multicenter, Single-Arm, Phase II Trial

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Development of the PREDICT-Kidney online tool to promote informed decision-making about kidney cancer follow-up care: a qualitative co-design study.

Differential Tumor Response Patterns and Extent of Necrosis After Immunotherapy Combinations Predict Clinical Responses for Renal Cell Carcinoma.

Optimizing management of small renal masses: a patient-centered approach to minimize overtreatment.

When Effective Therapies Collide: Aorto-Esophageal Fistula After Thoracic Radiotherapy and Anti-VEGF TKI in a Long-Survivor with mRCC.

Metabolic syndrome and risk of kidney cancer in the United States.

Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials.

Recurrence Risk Stratification in Clear Cell Renal Cell Carcinoma Using TNM 2017 and WHO/ISUP Grade.

What Are the Limitations of Measuring Bladder Compliance, As the Sole Indicator of Future Risk to the Upper Urinary Tract and Renal Function? ICI-RS 2025.

Towards a better understanding of kidney CANCER: Genetically engineered mouse models and biomarkers insights.

An explainable clinical-radiomics machine learning model for preoperative prediction of WHO/ISUP nuclear grade in clear cell renal cell carcinoma.

Percutaneous Image-Guided Non-Target Renal Biopsy in Cancer Patients: A Tertiary Cancer Center Experience.

Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.

Node Positive Resected Renal Cell Carcinoma Portends a Poor Prognosis: Results From the Canadian Kidney Cancer Collaboration - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Kidney Cancer Weekly

Renal Cancer

Login